RecruitingPhase 3NCT06207981
Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
Studying Carcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Federation Francophone de Cancerologie Digestive
- Principal Investigator
- Veronique Vendrely, Md-pHDUniversity Hospital, Bordeaux
- Intervention
- induction chemotherapy (mDCF)(drug)
- Enrollment
- 310 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2030
Study locations (30)
- AGEN-Cromg, Agen, France
- Clinique Calabet, Agen, France
- AIX EN PROVENCE CH Pays d'Aix, Aix-en-Provence, France
- Amiens - Clinique de L'Europe, Amiens, France
- ANTONY Hôpital Privé, Antony, France
- Argenteuil - Ch, Argenteuil, France
- ARRAS Les Bonnettes, Arras, France
- ARRAS Marie Curie, Arras, France
- AURILLAC-Henri Mondor, Aurillac, France
- Centre Medico Chirurgical, Aurillac, France
- AUXERRE CH GHT Unyon, Auxerre, France
- Avignon Icap, Avignon, France
- Avranches - Hopital Prive de La Baie, Avranches, France
- Bayonne- Clinique Belharra, Bayonne, France
- BEAUVAIS-Simone Veil, Beauvais, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Fondation ARCAD
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06207981 on ClinicalTrials.govOther trials for Carcinoma of the anal canal
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07029152Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure ProphylaxisUniversitair Ziekenhuis Brussel
- ACTIVE NOT RECRUITINGPHASE3NCT06866574A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesXiamen University
- RECRUITINGPHASE2NCT06640283Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesInstituto do Cancer do Estado de São Paulo
- RECRUITINGNANCT06792604Host Genome Methylation: a Screening Tool in Anal Cancer DetectionAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT05661188Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)Grupo Espanol Multidisciplinario del Cancer Digestivo
- RECRUITINGNCT06327568Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal SpecimensEuropean Institute of Oncology
- RECRUITINGNCT05438836Re-optimization Based Online Adaptive Radiotherapy of Anal CancerHerlev Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04432597HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersNational Cancer Institute (NCI)